Viking Therapeutics (VKTX) Competitors $25.16 -0.11 (-0.44%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, and ROIVShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability. Which has more volatility and risk, MDGL or VKTX? Madrigal Pharmaceuticals has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Which has preferable earnings & valuation, MDGL or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$180.13M53.76-$465.89M-$12.85-33.95Viking TherapeuticsN/AN/A-$109.96M-$1.53-16.35 Do analysts prefer MDGL or VKTX? Madrigal Pharmaceuticals currently has a consensus price target of $471.13, indicating a potential upside of 8.00%. Viking Therapeutics has a consensus price target of $86.92, indicating a potential upside of 247.39%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media refer more to MDGL or VKTX? In the previous week, Madrigal Pharmaceuticals had 17 more articles in the media than Viking Therapeutics. MarketBeat recorded 30 mentions for Madrigal Pharmaceuticals and 13 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.33 beat Madrigal Pharmaceuticals' score of 1.06 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MDGL or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Viking Therapeutics' return on equity of -19.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal Pharmaceuticals-54.68% -38.38% -27.32% Viking Therapeutics N/A -19.98%-19.38% Do insiders and institutionals have more ownership in MDGL or VKTX? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80B$3.15B$5.75B$10.05BDividend YieldN/A2.28%5.28%4.52%P/E Ratio-16.3021.3575.4126.14Price / SalesN/A426.45515.81170.32Price / CashN/A45.5837.2059.76Price / Book3.179.6111.546.19Net Income-$109.96M-$53.33M$3.28B$270.56M7 Day Performance-6.74%1.00%0.88%2.93%1 Month Performance-33.96%11.58%11.06%8.82%1 Year Performance-54.21%12.98%61.87%27.61% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.2826 of 5 stars$25.05-0.9%$86.92+247.0%-53.9%$2.82BN/A-16.3920Positive NewsMDGLMadrigal Pharmaceuticals4.2683 of 5 stars$437.85+0.2%$459.25+4.9%+88.0%$9.72B$180.13M-34.0790Positive NewsInsider TradeAnalyst RevisionLLYEli Lilly and Company5 of 5 stars$732.41+0.1%$950.17+29.7%-17.4%$693.20B$45.04B47.8747,000Trending NewsASNDAscendis Pharma A/S3.5476 of 5 stars$194.27+0.2%$243.36+25.3%+73.7%$11.89B$393.54M-37.651,017Positive NewsRDYDr. Reddy's Laboratories2.636 of 5 stars$14.20-0.1%$16.95+19.4%-8.2%$11.85B$3.81B21.5127,811Positive NewsQGENQiagen4.7074 of 5 stars$46.53+0.9%$49.69+6.8%+5.5%$10.34B$2.04B27.495,765Positive NewsBBIOBridgeBio Pharma4.2248 of 5 stars$51.76-1.5%$62.18+20.1%+74.3%$9.89B$235.81M-12.66400News CoveragePositive NewsInsider TradeMRNAModerna4.4709 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.06B-3.205,800ELANElanco Animal Health2.7497 of 5 stars$18.38-0.4%$17.33-5.7%+27.3%$9.13B$4.48B21.379,000High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.4531 of 5 stars$105.91+0.0%$109.00+2.9%+286.7%$8.67B$221.67M-106.9830Positive NewsROIVRoivant Sciences2.7688 of 5 stars$11.93-0.1%$16.50+38.3%+7.8%$8.15B$29.05M-17.04860News CoverageOptions Volume Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Ascendis Pharma A/S Competitors Dr. Reddy's Laboratories Competitors Qiagen Competitors BridgeBio Pharma Competitors Moderna Competitors Elanco Animal Health Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VKTX Stock Alerts